tiprankstipranks
ODI Pharma AB (DE:6OD)
FRANKFURT:6OD
Germany Market
Holding DE:6OD?
Track your performance easily

ODI Pharma AB (6OD) Income Statement

0 Followers

ODI Pharma AB Income Statement

Last quarter (Q2 2023), ODI Pharma AB's total revenue was kr73.28K, an increase of Infinity% from the same quarter last year. In Q2, ODI Pharma AB's net income was kr-1.74M. See ODI Pharma AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 22Jun 21Jun 20Jun 19
Total Revenue
kr 386.21Kkr 312.94Kkr 0.00kr 0.00kr 0.00
Cost of Revenue
kr 450.21Kkr 416.57Kkr 0.00--
Gross Profit
kr -64.00Kkr -103.64Kkr 0.00--
Operating Expense
kr 7.69Mkr 7.10Mkr 3.96Mkr 4.93Mkr 3.34M
Operating Income
kr -7.75Mkr -7.21Mkr -3.96Mkr -4.93Mkr -3.34M
Net Non Operating Interest Income Expense
kr -47.87Kkr -28.63Kkr -3.08Kkr -7.78Kkr -8.89K
Other Income Expense
-----
Pretax Income
kr -7.80Mkr -7.24Mkr -3.97Mkr -4.94Mkr -3.35M
Tax Provision
kr 3.87Kkr 3.51Kkr 14.37Kkr 20.05Kkr 282.86K
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
kr -7.80Mkr -7.24Mkr -3.98Mkr -4.96Mkr -3.63M
Basic EPS
kr -0.28-kr -0.26kr -0.36kr -0.48
Diluted EPS
kr -0.28-kr -0.26kr -0.36kr -0.48
Basic Average Shares
kr 30.44M-kr 15.22Mkr 15.22Mkr 7.61M
Diluted Average Shares
kr 30.44M-kr 15.22Mkr 15.22Mkr 15.22M
Dividend Per Share
-----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
kr 8.14Mkr 7.52Mkr 3.96Mkr 4.93Mkr 3.34M
Net Income From Continuing And Discontinued Operation
kr -7.80Mkr -7.24Mkr -3.98Mkr -4.96Mkr -3.63M
Normalized Income
kr -7.80Mkr -7.24Mkr -3.98Mkr -4.96Mkr -3.63M
Interest Expense
kr 55.64Kkr 28.76Kkr 14.57Kkr 7.80Kkr 8.92K
EBIT
kr -7.74Mkr -7.21Mkr -3.95Mkr -4.93Mkr -3.34M
EBITDA
kr -7.73Mkr -7.20Mkr -3.95Mkr -4.92Mkr -3.34M
Currency in SEK

ODI Pharma AB Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis